8-K
InMed Pharmaceuticals Inc. (INM)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):June 24, 2025
INMED PHARMACEUTICALS
INC.
(Exact Name of Company as Specified in Charter)
| British Columbia | 001-39685 | 98-1428279 |
|---|---|---|
| (State or Other Jurisdiction of Incorporation) | (Commission File Number) | (IRS Employer Identification No.) |
| InMed Pharmaceuticals Inc.<br><br> <br>Suite 1445 - 885 W. Georgia Street,<br><br> <br>Vancouver, B.C.<br><br> <br>Canada | V6C 3E8 | |
| --- | --- | |
| (Address of Principal Executive Offices) | (Zip Code) |
Company’s telephone number, including
area code: (604) 669-7207
Not applicable
(Former Name or Former Address, if Changed SinceLast Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|---|---|
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| --- | --- |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| --- | --- |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| --- | --- |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
|---|---|---|
| Common Shares, no par value | INM | The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 7.01 Regulation FD Disclosure.
On June 24, 2025, the Company announced new preclinical data demonstrating that INM-901 significantly reduces inflammation in ex vivo models of neuroinflammation, further supporting its potential as a therapeutic candidate in Alzheimer’s disease.
The information set forth in this Item 7.01, including Exhibits 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. The information set forth in this Item 7.01, including Exhibit 99.1, shall not be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits:
The following exhibits shall be deemed to be furnished, and not filed:
| Exhibit No. | Description |
|---|---|
| 99.1 | News release, dated June 24, 2025 |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document and included as Exhibit 101) |
1
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| INMED PHARMACEUTICALS INC. | ||
|---|---|---|
| Date: June 24, 2025 | By: | /s/ Eric A Adams |
| Eric A Adams <br><br>President & CEO |
2
Exhibit 99.1
| NASDAQ: INM<br><br> <br>****<br><br> <br>1445 – 885 West Georgia St.<br><br> <br>Vancouver, BC, Canada V6C 3E8<br><br> <br>Tel: +1.604.669.7207<br><br> <br>Email: info@inmedpharma.com<br><br> <br>www.inmedpharma.com |
|---|
InMed’s INM-901 Significantly Reduces Neuroinflammation in Alzheimer’s Disease Ex Vivo Study
| ● | Demonstrates statistically significant reduction<br>of pro-inflammatory cytokines, including IL-6, IL-1β, IL-2, and KC/Gro |
|---|---|
| ● | Significantly reduces levels of inflammasome<br>marker, NLRP3, a key contributor to neurodegeneration |
| --- | --- |
| ● | Reduces key pro-inflammatory markers, independent<br>of amyloid beta or tau pathology |
| --- | --- |
Vancouver, British Columbia – June 24, 2025. InMed Pharmaceuticals Inc. (NASDAQ: INM) (“InMed” or the “Company”), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announced new preclinical data demonstrating that INM-901 significantly reduces inflammation in ex vivo models of neuroinflammation, further supporting its potential as a therapeutic candidate in Alzheimer’s disease.
The study evaluated INM-901 in an ex vivo model of lipopolysaccharide (LPS)-induced inflammation in animal brain tissue, which is designed to induce a strong expression of pro-inflammatory cytokines IL-6, IL-1β, IL-2, and KC/Gro and inflammasome marker NLRP3. Results demonstrated that INM-901 treatment can reduce pro-inflammatory cytokines and may have a direct impact on neuroinflammation independent of the influence of amyloid beta or tau aggregation. This study model offers insight into INM-901’s potential therapeutic impact on brain inflammation that may underlie a broad range of neurodegenerative diseases, including Alzheimer’s disease.
Key Findings from the Study:
| ● | INM-901 significantly reduced levels of NLRP3and IL-1β, two inflammasome markers increasingly implicated in the pathogenesis of Alzheimer’s disease and other neuroinflammatory<br>diseases. |
|---|---|
| ● | INM-901 treatment resulted in a dose-dependentand statistically significant reduction in several key pro-inflammatory markers, including IL-6, IL-1β, KC/Gro, and IL-2. |
| --- | --- |
| ● | INM-901 reduced key pro-inflammatory markers,<br>independent of amyloid-beta or tau pathology, signifying potential to treat other dementia-related diseases. |
| --- | --- |
“NLRP3-driven inflammation is recognized as a key contributor to neurodegenerative disease progression,” said Dr. Eric Hsu, SVP of Preclinical Research & Development. “The data derived from this LPS-induced inflammation study further support our previous findings in the amyloid beta animal model following INM-901 treatment, which demonstrated a significant reduction in inflammatory markers. Notably, the results from the LPS study suggest that INM-901 exerts a direct effect on neuroinflammation, independent of the contributions from amyloid beta plaques or tau aggregation.”
NLRP3 has been implicated in the pathogenesis of several inflammatory, autoimmune, metabolic and neurodegenerative conditions such as Alzheimer’s disease, Parkinson’s, type 2 diabetes and others. In these diseases, overactivation of NLRP3 can result in chronic inflammation in the brain, which may contribute to neurodegeneration and cognitive decline.
This most recent study represents a key advancement for the program, highlighting INM-901 as a distinctive and promising therapeutic candidate for the treatment of Alzheimer’s disease and supports continued development toward a lead indication in Alzheimer’s disease. The Company plans to advance INM-901 through additional preclinical studies, with IND-enabling studies to follow.
INM-901: Program Summary to date:
INM-901 is a proprietary small molecule drug candidate for Alzheimer’s disease with potentially multiple mechanisms of action. Key characteristics of INM-901 include:
| ● | demonstrates reduced neuroinflammation and improved<br>neurite growth and neuronal function, indicating the potential to restore damage caused by Alzheimer’s disease; |
|---|---|
| ● | is a preferential signaling agonist of the CB1/CB2<br>receptors and has been shown to have neuroprotective effects, helping protect the neurons in the brain from damage and cell death; |
| --- | --- |
| ● | impacts the peroxisome proliferator-activated<br>receptors (“PPARs”), which have been shown to play an important role in diabetes and are also considered as one of the potential<br>therapeutic targets for neurodegenerative disorders such as Alzheimer’s disease; |
| --- | --- |
| ● | can be administered orally and achieve therapeutic<br>levels in the brain comparable to those obtained through intraperitoneal injection, offering many potential advantages over routes of<br>administration of the currently approved products; and |
| --- | --- |
| ● | demonstrates significant improvement in cognitive<br>function, memory, locomotor activity, anxiety-based behavior and sound awareness in long-term preclinical behavioural studies. |
| --- | --- |
To learn more about INM-901 please visit the website at: https://www.inmedpharma.com/pharmaceutical/inm-901-for-alzheimers-disease/
About InMed:
InMed Pharmaceuticals is a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates targeting the CB1/CB2 receptors. InMed’s pipeline consists of three separate programs in the treatment of Alzheimer’s, ocular and dermatological indications. For more information, visit www.inmedpharma.com.
Investor Contact:
Colin Clancy
Vice President, Investor Relations
and Corporate Communications
T: +1 604 416 0999
E: ir@inmedpharma.com
2
Cautionary Note Regarding Forward-Looking Information:
This news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking information”) within the meaning of applicable securities laws. Forward-looking statements are frequently, but not always, identified by words such as “expects”, “anticipates”, “believes”, “intends”, “potential”, “possible”, “would” and similar expressions. Such statements, based as they are on current expectations of management, inherently involve numerous risks, uncertainties and assumptions, known and unknown, many of which are beyond our control. Forward-looking information is based on management’s current expectations and beliefs and is subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Without limiting the foregoing, forward-looking information in this news release includes, but is not limited to, statements about: the efficacy of INM-901, INM-901’s potential impact on inflammation, INM-901’s impact on neuroinflammation independent of amyloid beta or tau pathology, the role of NLRP3 in the pathogenesis of several neurodegenerative conditions, INM-901’s ability to treat Alzheimer’s, marketability and uses for INM-901, the results of further studies into INM-901 and continued development of InMed’s Alzheimer’s program.
Additionally, there are known and unknown risk factors which could cause InMed’s actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein. A complete discussion of the risks and uncertainties facing InMed’s stand-alone business is disclosed in InMed’s Annual Report on Form 10-K, in Item 1A. of the Quarterly Report for the period ended March 31, 2025, and other filings with the Securities and Exchange Commission on www.sec.gov.
All forward-looking information herein is qualified in its entirety by this cautionary statement, and InMed disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.
3